Seoul National University Hospital

Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.

Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.

A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.

Led MONALEESA-7, which proved a CDK4/6 inhibitor extends survival in premenopausal breast cancer, and steers Korea's breast cancer trial network.

A GI oncologist and genomics researcher who leads precision oncology and colorectal cancer trials at Seoul National University.

Principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive gastric cancer, and a founder of Korean phase 1 oncology.